364 results
Page 11 of 19
8-K
EX-99.1
ug1 g58472abg4p
4 Mar 11
Bristol-Myers Squibb Names Elliott Sigal, M.D., Ph.D., to
12:00am
8-K
EX-99.1
728ebgphtqwutv4yzv7
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
6mxw1xnyvalg s20
9 Nov 10
Bristol-Myers Squibb Announces Cash Tender Offer For Up to $750 Million
12:00am
8-K
EX-99.1
rps76 455t8n
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
8-K
EX-99.1
lbd6n9zne 3h
12 Oct 10
Other Events
12:00am
SC TO-T/A
EX-99
oha yi7kzcsn304
13 Sep 10
Third party tender offer statement (amended)
12:00am
8-K
EX-99.1
40f590c0gbw3aygmm
10 Sep 10
Bristol-Myers Squibb to Acquire ZymoGenetics
12:00am
SC TO-C
ll2u1h08arssl6c
7 Sep 10
Information about tender offer
12:00am
8-K
EX-99.1
2ymnh jqe
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am
8-K
EX-99.1
kl2l43pstrhri 3psjx
24 Dec 09
Bristol-Myers Squibb and Mead Johnson Announce
12:00am
425
8utsmr tkz5
23 Dec 09
Business combination disclosure
12:00am
425
enna2md2c4ept 19m
23 Dec 09
Business combination disclosure
12:00am